Middle East and Africa Molecular Diagnostics Market Growth Outlook
Meticulous Research®—a leading market research company, published a research report titled, ‘Middle East & Africa Molecular Diagnostics Market by Offering (Reagents, Kits, Systems, Software) Test Type (Lab, PoC) Technology (PCR, ISH, INAAT, Sequencing, Microarray) Application (Influenza, HPV, Oncology, Gene Testing) End User - Forecast to 2032’
According to this latest publication
from Meticulous Research®, the Middle East & Africa molecular
diagnostics market is projected to reach $1.16
billion by 2032, at a CAGR of 5.4% from 2025 to 2032. The growth of the
Middle East & Africa molecular diagnostics market is driven by factors such
as the rising prevalence of communicable and non-communicable diseases,
technological advancements in molecular diagnostics, increasing investments and
funding aimed at enhancing healthcare systems in the Middle East & Africa,
and the rising healthcare expenditure in the region. However, inconsistencies
in medical device regulations across the Middle East & Africa and the high
costs of molecular diagnostic tests restrain the market’s growth.
Emerging medical and wellness tourism
in the UAE and a growing focus on companion diagnostics are expected to create
market growth opportunities. However, the shortage of skilled professionals
poses a significant challenge to the growth of this market.
Key Players
The key players profiled in the Middle
East & Africa molecular diagnostics market report are AstraGene LLC
(U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific
Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.),
AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation
(U.S.), Abbott Laboratories (U.S), and Agilent Technologies, Inc. (U.S.).
The Middle East & Africa molecular
diagnostics market is segmented by Offering (Kits & Reagents, Instruments,
Software & Services), Test Type (Laboratory Tests and Point-of-Care [POC]
Tests), Technology (Polymerase Chain Reaction [PCR], In Situ Hybridization
[ISH], Isothermal Nucleic Acid Amplification Technology [INAAT], Microarrays,
Sequencing, Mass Spectrometry, and Other Technologies), Application (Infectious
Diseases [Respiratory Diseases, Hepatitis, HIV, Chlamydia Trachomatis/Neisseria
Gonorrhoeae, Human Papillomavirus {HPV}, Healthcare-Associated Infections
{HAIs}, and Other Infectious Diseases], Oncology [Breast Cancer, Colorectal
Cancer, Lung Cancer, Prostate Cancer, Lymphoma, Leukemia, Cervical Cancer, and
Other Cancer Types], Genetic Testing, Neurological Diseases, Cardiovascular
Diseases, and Other Applications), End User (Hospitals & Clinics,
Diagnostic Laboratories, Academic & Research Institutes, and Other End
Users), and geography. The study also evaluates industry competitors and analyzes
the regional and country-level markets.
Among the offerings studied in this
report, in 2025, the kits
and reagents segment is expected to account for the largest share of the
market. The large market share of this segment is attributed to the wide
availability of a diverse range of diagnostic reagents & consumables and
the growing awareness regarding the importance of early disease diagnosis. For
instance, in September 2024, the World Health Organization (WHO) Regional
Office for Africa, along with the support of F. Hoffmann-La Roche Ltd.
(Switzerland), launched an initiative in Cote d’Ivoire, Kenya, and Zimbabwe to
provide health promotion, detection, screening, and early diagnosis and
treatment of breast and cervical cancer. This initiative was aimed at providing
an integrated and holistic system of healthcare that will contribute to addressing
the burden of breast and cervical cancer in the African region.
Among the test types studied in
this report, in 2025, the
laboratory test segments is expected to account for the largest share of the
market. The large market share of this segment can be attributed to the
substantial number of laboratory tests conducted in hospitals and laboratories
due to the high accuracy of the test results. Furthermore, the expansion and
enhancement of diagnostic laboratory networks in the region also contribute to
the segment's significant market share. For instance, in December 2021, 54gene
(Nigeria) launched a chain of diagnostic labs named 7RiverLabs. These labs are
equipped with state-of-the-art technology, offering world-class,
cost-effective, speedy, reliable, and advanced molecular diagnostics to
healthcare providers and patients.
Among the technologies studied in
this report, in 2025, the
polymerase chain reaction (PCR) segment is expected to account for the largest
share of the market. The large market share of this segment can be attributed
to the high specificity and sensitivity of the instrument, along with technological
advancements in PCR technology. Additionally, the improved PCR testing
capabilities in laboratories and the introduction of new products during the
COVID-19 pandemic to address the growing burden contribute to the growth of
this segment. For instance, in February 2022, F. Hoffmann-La Roche Ltd.
(Switzerland) expanded its COVID-19 PCR portfolio with the introduction of the
cobas 5800 system in countries accepting the CE mark. This expansion includes
the cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B
tests, offering standardized performance and efficiencies in addressing various
molecular laboratory testing needs across low, medium, and high volumes.
Among the applications studied in
this report, in 2025, the
infectious diseases segment is expected to account for the largest share of the
market. The large market share of this segment can be attributed to the growing
prevalence of infectious diseases and the rise in funding allocated for the
development of new diagnostic tools for infectious diseases. According to the
World Health Organization (WHO), in 2022, there were a total of 249 million
cases of malaria worldwide, with the African region accounting for 94% of these
cases. The rising incidence of such infections drives the demand for rapid,
user-friendly, and cost-effective infectious disease testing tools.
Among the end users studied in this
report, in 2025, the
hospitals & clinics segment is expected to account for the largest share of
the market. The large market share of this segment can be attributed to the
increased number of hospitalizations due to various diseases that necessitate
molecular diagnosis. Additionally, the proliferation of hospitals and clinics
in emerging countries contributes to the growing utilization of molecular
diagnostic products. The expansion of hospitals in the Middle East & Africa
further drives the demand for molecular diagnostic tests. For instance, in
April 2024, Burjeel Holdings (UAE.) partnered with OncoHelix, Inc. (U.S.) to
establish a state-of-the-art laboratory in Abu Dhabi (UAE), offering advanced
molecular diagnostics, cellular, and immunological profile testing for patients
in the UAE.
Among the countries studied in this
report, in 2025, Saudi
Arabia is expected to account for the largest share of the market. The large
market share of this segment can be attributed to factors such as the high
disease burden of both communicable and non-communicable diseases, the
widespread adoption of molecular diagnostics in laboratory tests, ongoing
improvements in the healthcare infrastructure, and rising healthcare
expenditure.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5791
Key questions answered in the
report:
·
Which are
the high-growth market segments in terms of molecular diagnostics in the Middle
East & Africa by offering, test type, technology, application, end user,
and geography?
·
What was
the historical market for molecular diagnostics across the Middle East &
Africa?
·
What are
the market forecasts and estimates for the period 2025–2032?
·
What are
the major drivers, restraints, opportunities, and challenges in the Middle East
& Africa molecular diagnostics market?
·
Who are
the major players in the Middle East & Africa molecular diagnostics market?
·
What is
the competitive landscape like, and who are the market leaders in the Middle
East & Africa molecular diagnostics market?
·
What are
the recent developments in the Middle East & Africa molecular diagnostics
market?
·
What are
the different strategies adopted by the major players in the Middle East &
Africa molecular diagnostics market?
·
What are
the geographical trends and high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment